Antiplatelet therapy in percutaneous coronary intervention: Recent advances in oral antiplatelet agents

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 305-311

  Wong, Yee W ^a   Prakash, Roshan ^a   Chew, Derek P ^b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

antiplatelet therapy; clopidogrel; PCI; prasugrel; ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MECHANISM; DYSPNEA; GENETIC POLYMORPHISM; HUMAN; LOADING DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP3A; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PYRIDINES; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 77953808995     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328339f1aa     Document Type: Review

References (50)

1. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46:937-954.
2. Bates ER, McGillem MJ, Beals TF, et al. Effect of angioplasty-induced endothelial denudation compared with medial injury on regional coronary blood flow. Circulation 1987; 76:710-716.
3. Rodgers GP, Minor ST, Robinson K, et al. The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and nonaspirin- treated swine model. Am Heart J 1991; 122:640-647.
4. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051-1058.
5. Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:728S-741S.
6. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97:211-218.
7. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic- drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
8. Hall D, Gruentzig A. Percutaneous transluminal coronary angioplasty: current procedure and future direction. AJR Am J Roentgenol 1984; 142: 13-16. (Pubitemid 14218799)
9. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318:1714-1719.
10. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65:422-426.
11. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597-1603.
12. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629.
13. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
14. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. J Am Med Assoc 2005; 294:1224-1232.
15. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288:2411-2420.
16. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pretreatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939-943.
17. Steinhubl S, Roe MT. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drug Rev 2007; 25:188-203.
18. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099-2106.
19. Williams DO, Abbott JD. What to do with patients receiving long-term clopidogrel: reload or relax? Circulation 2008; 118:1219-1222.
20. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 2008; 118:1225-1233.
21. Mehta SR, Bassand J-P, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-STelevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156:1080-1180.
22. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003; 92:651-655.
23. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104:2767-2771.
24. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
25. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216.
26. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
27. Vila PM, Zafar MU, Badimon JJ. Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. Platelets 2009; 20:531-538.
28. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43:1122-1126.
29. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829-1843.
30. Kereiakes DJ, Gurbel PA. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. JACC Cardiovasc Interv 2008; 1:111-121.
31. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
32. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of periinterventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742-1750.
33. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl JMed 2009; 360:363-375.
34. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
35. Bonello L, Bonello-Palot N, Armero S, et al. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 2010; 125:e167-170.
36. Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. AJC 2007; 99:1518-1522.
37. Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of 'resistance'. Am Heart J 2009; 158:925-932.
38. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
39. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2009 [Epub ahead of print].
40. Lazar LD, Lincoff AM. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Clev Clin J Med 2009; 76:707-714.
41. Guerra DR, Tcheng JE. Prasugrel: clinical development and therapeutic application. Adv Ther 2009; 26:999-1011.
42. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373:723-731.
43. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118:1626-1636.
44. Bhatt DL. Antiplatelet therapy: ticagrelor in ACS-what does PLATO teach us? Nature Rev Cardiol 2009; 6:737-738.
45. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599-605.
46. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
47. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375:283-293.
48. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent 2009; 2:222-229.
49. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330-2341.
50. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318-2329.